Comorbidities in Mycosis Fungoides and Racial Differences in Co-Existent Lymphomatoid Papulosis: A Cross-Sectional Study of 580 Patients in an Urban Tertiary Care Center
Abstract
:1. Introduction
2. Materials and Methods
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Conflicts of Interest
Appendix A
Comorbidity | MF, n (%) | AD, n (%) | OR (95% CI) | p Value | Psoriasis, n (%) | OR (95% CI) | p Value | Gen Pop, n (%) | OR (95% CI) | p Value |
---|---|---|---|---|---|---|---|---|---|---|
Allergic Contact Dermatitis | 6 (1.0) | 428 (4.1) | 0.2 (0.1–0.5) | <0.001 | 137 (0.9) | 1.1 (0.5–2.6) | 0.75779 | 4876 (0.1) | 10.6 (4.7–23.7) | <0.001 |
Alzheimer Disease | 5 (0.9) | 27 (0.3) | 3.3 (1.3–8.7) | 0.00892 | 105 (0.7) | 1.2 (0.5–3.0) | 0.64202 | 8882 (0.2) | 4.8 (2.0–11.7) | <0.001 |
Asthma | 38 (6.6) | 2223 (21.4) | 0.3 (0.2–0.4) | <0.001 | 1529 (10.2) | 0.6 (0.4–0.9) | 0.00454 | 109,109 (2.2) | 3.1 (2.2–4.3) | <0.001 |
Atopic Dermatitis | 23 (4.0) | 369 (2.5) | 1.6 (1.1–2.5) | 0.02214 | 10,358 (0.2) | 19.7 (13.0–29.9) | <0.001 | |||
Atrial Fibrillation | 32 (5.5) | 284 (2.7) | 2.1 (1.4–3.0) | <0.001 | 931 (6.2) | 0.9 (0.6–1.3) | 0.51122 | 68,394 (1.4) | 4.2 (2.9–5.9) | <0.001 |
Autistic Disorder | 0 (0) | 50 (0.5) | 0 | 0.09391 | 19 (0.1) | 0 | 0.39189 | 2371 (0.0) | 0 | 0.59782 |
Breast Cancer | 2 (0.3) | 33 (0.3) | 1.1 (0.3–4.5) | 0.91079 | 76 (0.5) | 0.7 (0.2–2.8) | 0.59126 | 7509 (0.2) | 2.3 (0.6–9.1) | 0.23285 |
Chronic Hepatitis C | 3 (0.5) | 130 (1.3) | 0.4 (0.1–1.3) | 0.11564 | 214 (1.4) | 0.4 (0.1–1.1) | 0.06769 | 13,952 (0.3) | 1.8 (0.6–5.7) | 0.28601 |
Chronic Kidney Disease | 41 (7.1) | 446 (4.3) | 1.7 (1.2–2.4) | 0.00161 | 950 (6.3) | 1.1 (0.8–1.6) | 0.46281 | 57,386 (1.2) | 6.5 (4.7–8.9) | <0.001 |
Colon Cancer | 0 (0) | 8 (0.1) | 0 | 0.50364 | 27 (0.2) | 0 | 0.3073 | 2561 (0.1) | 0 | 0.5835 |
Congestive Heart Failure | 37 (6.4) | 287 (2.8) | 2.4 (1.7–3.4) | <0.001 | 675 (4.5) | 1.5 (1.0–2.0) | 0.03177 | 43,133 (0.9) | 7.7 (5.5–10.8) | <0.001 |
COPD | 36 (6.2) | 424 (4.1) | 1.6 (1.1–2.2) | 0.01308 | 961 (6.4) | 1.0 (0.7–1.4) | 0.86328 | 51,410 (1.0) | 6.3 (4.5–8.8) | <0.001 |
Diabetes Mellitus Type 2 | 64 (11.0) | 103 (9.7) | 1.2 (0.9–1.5) | 0.27746 | 2191 (14.6) | 0.7 (0.6–0.9) | 0.01782 | 136,538 (2.8) | 4.4 (3.4–5.7) | <0.001 |
HIV | 3 (0.5) | 185 (1.8) | 0.3 (0.1–0.9) | 0.02243 | 144 (1.0) | 0.5 (0.4–0.7) | 0.28188 | 13,283 (0.3) | 1.9 (0.6–6.0) | 0.24755 |
Hodgkin’s Disease | 7 (1.2) | 10 (0.1) | 12.7 (4.8–33.4) | <0.001 | 20 (0.1) | 9.2 (3.9–21.8) | <0.001 | 1631 (0.0) | 37.0 (17.5–78.1) | <0.001 |
Hyperlipidemia | 155 (26.7) | 2736 (26.4) | 1.0 (0.8–1.2) | 0.84364 | 5,812 (38.6) | 0.6 (0.5–0.7) | <0.001 | 335,534 (6.8) | 5.0 (4.2–6.0) | <0.001 |
Hypertension | 194 (33.4) | 2991 (28.8) | 1.2 (1.0–1.5) | 0.01664 | 6128 (40.7) | 0.7 (0.6–0.9) | <0.001 | 427,318 (8.6) | 5.3 (4.5–6.3) | <0.001 |
Inflammatory Bowel Disease | 5 (0.9) | 94 (0.9) | 1.0 (0.4–2.3) | 0.91448 | 228 (1.5) | 0.6 (0.2–1.4) | 0.203 | 8817 (0.2) | 4.9 (2.0–11.7) | <0.001 |
Ischemic Heart Disease | 53 (9.1) | 512 (4.9) | 1.9 (1.4–2.6) | <0.001 | 1274 (8.5) | 1.1 (0.8–1.5) | 0.56805 | 79,665 (1.6) | 6.1 (4.6–8.1) | <0.001 |
Ischemic Stroke | 0 (0) | 23 (0.2) | 0 | 0.25649 | 37 (0.2) | 0 | 0.23189 | 2715 (0.1) | 0 | 0.5724 |
Lung Cancer | 3 (0.5) | 30 (0.3) | 1.8 (0.5–5.9) | 0.32876 | 83 (0.6) | 0.9 (0.3–3.0) | 0.91295 | 7229 (0.1) | 3.6 (1.1–11.0) | 0.01939 |
Lymphomatoid Papulosis | 11 (1.9) | 4 (0.0) | 50.2 (15.9–158) | <0.001 | - | 0 | <0.001 | 49 (0.0) | 1950.5 (1009.0–3770.4) | <0.001 |
Major Depressive Disorder | 44 (7.6) | 1340 (12.9) | 0.6 (0.4–0.8) | <0.001 | 2091 (13.9) | 0.5 (0.4–0.7) | <0.001 | 119,308 (2.4) | 3.3 (2.4–4.5) | <0.001 |
Malignant Melanoma | 9 (1.6) | 70 (0.7) | 2.3 (1.2–4.7) | 0.01504 | 164 (1.1) | 1.4 (0.7–2.8) | 0.29657 | 7879 (0.2) | 9.9 (5.1–19.1) | <0.001 |
Osteoarthritis | 80 (13.8) | 1689 (16.3) | 0.8 (0.6–1.0) | 0.11477 | 3981 (26.5) | 0.4 (0.4–0.6) | <0.001 | 187,109 (3.8) | 4.1 (3.2–5.2) | <0.001 |
Osteoporosis | 13 (2.2) | 417 (4.0) | 0.5 (0.3–1.0) | 0.0321 | 870 (5.8) | 0.4 (0.2–0.7) | <0.001 | 44,238 (0.9) | 2.5 (1.4–4.4) | <0.001 |
Psoriasis | 23 (4.0) | 369 (3.6) | 1.1 (0.7–1.7) | 0.60368 | 15,028 (0.3) | 13.5 (8.9–20.6) | <0.001 | |||
Rheumatoid Arthritis | 8 (1.4) | 128 (1.2) | 1.1 (0.5–2.3) | 0.75656 | 493 (3.3) | 0.4 (0.2–0.8) | 0.01095 | 11,071 (0.2) | 6.2 (3.1–12.5) | <0.001 |
Schizophrenia | 2 (0.3) | 73 (0.7) | 0.5 (0.1–2.0) | 0.30831 | 71 (0.5) | 0.7 (0.2–3.0) | 0.66003 | 8507 (0.2) | 2.0 (0.5–8.0) | 0.31551 |
Venous Thrombosis | 26 (4.5) | 268 (2.6) | 1.8 (1.2-2.7) | 0.00581 | 496 (3.3) | 1.4 (0.9-2.1) | 0.11836 | 34,113 (0.7) | 6.8 (4.6–10.0) | <0.001 |
Vitamin D Deficiency | 65 (11.2) | 2052 (19.8) | 0.5 (0.4–0.7) | <0.001 | 2996 (19.9) | 0.5 (0.4–0.7) | <0.001 | 132,446 (2.7) | 4.6 (3.5–5.9) | <0.001 |
Comorbidity | MF, n (%) | AD, n (%) | OR (95% CI) | p Value | Psoriasis, n (%) | OR (95% CI) | p Value | Gen Pop, n (%) | OR (95% CI) | p Value |
---|---|---|---|---|---|---|---|---|---|---|
Allergic Contact Dermatitis | 2 (1.1) | 118 (2.8) | 0.4 (0.1–1.5) | 0.15571 | 22 (1.3) | 0.8 (0.2–3.5) | 0.77179 | 893 (0.1) | 11.2 (2.8–45.3) | <0.001 |
Alzheimer Disease | 2 (1.1) | 10 (0.2) | 4.6 (1.0–20.9) | 0.03255 | 11 (0.7) | 1.6 (0.4–7.4) | 0.52635 | 1742 (0.2) | 5.8 (1.4–23.2) | 0.00532 |
Asthma | 18 (9.5) | 1240 (28.9) | 0.3 (0.2–0.4) | <0.001 | 266 (15.7) | 0.6 (0.3–0.9) | 0.02221 | 40,063 (4.2) | 2.4 (1.4–3.8) | <0.001 |
Atopic Dermatitis | 11 (5.8) | 93 (5.5) | 1.1 (0.6–2.0) | 0.86989 | 4276 (0.5) | 13.5 (7.3–24.9) | <0.001 | |||
Atrial Fibrillation | 13 (6.8) | 74 (1.7) | 4.2 (2.3–7.7) | <0.001 | 75 (4.4) | 1.6 (0.9–2.9) | 0.13687 | 10,168 (1.1) | 6.7 (3.8–11.9) | <0.001 |
Autistic Disorder | 17 (0.4) | 0 | 0.38448 | 6 (0.4) | 0 | 0.41072 | 687 (0.1) | 0 | 0.70994 | |
Breast Cancer | 2 (1.1) | 13 (0.3) | 3.5 (0.8–15.6) | 0.08025 | 10 (0.6) | 1.8 (0.4–8.2) | 0.44942 | 1465 (0.2) | 6.8 (1.7–27.6) | 0.00168 |
Chronic Hepatitis C | 2 (1.1) | 95 (2.2) | 0.5 (0.1–1.9) | 0.28112 | 64 (3.8) | 0.3 (0.1–1.1) | 0.05218 | 7057 (0.7) | 1.4 (0.4–5.7) | 0.62517 |
Chronic Kidney Disease | 18 (9.5) | 224 (5.2) | 1.9 (1.1–3.1) | 0.01127 | 179 (10.6) | 0.9 (0.5–1.5) | 0.63332 | 20,616 (2.2) | 4.7 (2.9–7.6) | <0.001 |
Colon Cancer | 1 (0.0) | 0 | 0.83324 | 2 (0.1) | 0 | 0.63519 | 461 (0.0) | 0 | 0.76064 | |
Congestive Heart Failure | 17 (8.9) | 136 (3.2) | 3.0 (1.8–5.1) | <0.001 | 115 (6.8) | 1.3 (0.8–2.3) | 0.2731 | 13,103 (1.4) | 7.0 (4.2–11.5) | <0.001 |
COPD | 13 (6.8) | 195 (4.5) | 1.5 (0.9–2.8) | 0.14163 | 120 (7.1) | 1.0 (0.5–1.7) | 0.89518 | 13,161 (1.4) | 5.2 (3.0–9.1) | <0.001 |
Diabetes Mellitus Type 2 | 34 (17.9) | 525 (12.2) | 1.6 (1.1–2.3) | 0.02118 | 379 (22.4) | 0.8 (0.5–1.1) | 0.15263 | 47,086 (50.) | 4.2 (2.9–6.0) | <0.001 |
HIV | 3 (1.6) | 158 (3.7) | 0.4 (0.1–1.3) | 0.12699 | 75 (4.4) | 0.3 (0.1–1.1) | 0.06099 | 8937 (0.9) | 1.7 (0.5–5.3) | 0.36796 |
Hodgkin’s Disease | 2 (1.1) | 2 (0.0) | 22.8 (3.2–162.7) | <0.001 | 2 (0.1) | 9.0 (1.3–64.1) | 0.00805 | 273 (0.0) | 36.8 (9.1–148.9) | <0.001 |
Hyperlipidemia | 48 (25.3) | 961 (22.4) | 1.2 (0.8–1.6) | 0.35813 | 632 (37.4) | 0.6 (0.4–0.8) | <0.001 | 72,033 (7.6) | 4.1 (3.0–5.7) | <0.001 |
Hypertension | 81 (42.6) | 1333 (31.1) | 1.6 (1.2–2.2) | <0.001 | 884 (52.3) | 0.7 (0.5–0.9) | 0.01141 | 127,879 (13.5) | 4.7 (3.6–6.3) | <0.001 |
IBS | 2 (1.1) | 28 (0.7) | 1.6 (0.4–6.8) | 0.50894 | 18 (1.1) | 1.0 (0.2–4.3) | 0.98734 | 1363 (0.1) | 7.4 (1.8–29.7) | <0.001 |
Ischemic Heart Disease | 20 (10.5) | 243 (5.7) | 2.0 (1.2–3.2) | 0.00533 | 183 (10.8) | 1.0 (0.6–1.6) | 0.89878 | 21,833 (2.3) | 5.0 (3.1–7.9) | <0.001 |
Ischemic Stroke | 7 (0.2) | 0 | 0.57723 | 6 (0.4) | 0 | 0.41072 | 847 (0.1) | 0 | 0.6796 | |
Lung Cancer | 1 (0.5) | 8 (0.2) | 2.8 (0.4–22.7) | 0.30631 | 14 (0.8) | 0.6 (0.1–4.8) | 0.65722 | 1321 (0.1) | 3.8 (0.5–27.0) | 0.15429 |
Lymphomatoid Papulosis | 1 (0.0) | 0 | 0.83324 | 7 (0.0) | 0 | 0.97006 | ||||
Major Depressive Disorder | 18 (9.5) | 615 (14.3) | 0.6 (0.4–1.0) | 0.05928 | 265 (15.7) | 0.6 (0.3–0.9) | 0.0233 | 29,514 (3.1) | 3.2 (2.0–5.3) | <0.001 |
Malignant Melanoma | 3 (0.1) | 0 | 0.71529 | 177 (0.0) | 0 | 0.8503 | ||||
Osteoarthritis | 28 (14.7) | 643 (15.0) | 1.0 (0.7–1.5) | 0.92114 | 433 (25.6) | 0.5 (0.3–0.8) | <0.001 | 44,608 (4.7) | 3.5 (2.3–5.2) | <0.001 |
Osteoporosis | 2 (1.1) | 83 (1.9) | 0.5 (0.1–2.2) | 0.38258 | 75 (4.4) | 0.2 (0.1–0.9) | 0.0256 | 5538 (0.6) | 1.8 (0.4–7.3) | 0.40015 |
Psoriasis | 9 (4.7) | 93 (2.2) | 2.2 (1.1–4.5) | 0.02029 | 1681 (0.2) | 27.9 (14.2–54.5) | <0.001 | |||
Rheumatoid Arthritis | 3 (1.6) | 54 (1.3) | 1.3 (0.4–4.1) | 0.70085 | 60 (3.6) | 0.4 (0.1–1.4) | 0.15226 | 13,171 (1.4) | 1.1 (0.4–3.5) | 0.82869 |
Schizophrenia | 53 (1.2) | 0 | 0.12313 | 24 (1.4) | 0 | 0.09829 | 5083 (0.5) | 0 | 0.31056 | |
Venous Thrombosis | 10 (5.3) | 114 (2.7) | 2.0 (1.0–3.9) | 0.03233 | 74 (4.4) | 1.2 (0.6–2.4) | 0.57583 | 9077 (1.) | 5.7 (3.0–10.8) | <0.001 |
Vitamin D Deficiency | 30 (15.8) | 882 (20.6) | 0.7 (0.5–1.1) | 0.10909 | 433 (25.6) | 0.5 (0.4–0.8) | 0.00286 | 38,158 (4.0) | 4.5 (3.0–6.6) | <0.001 |
Comorbidity | MF, n (%) | AD, n (%) | OR (95% CI) | p Value | Psoriasis, n (%) | OR (95% CI)2 | p Value | Gen Pop, n (%) | OR (95% CI) | p Value |
---|---|---|---|---|---|---|---|---|---|---|
Allergic Contact Dermatitis | 4 (1.2) | 249 (5.5) | 0.2 (0.1–0.6) | <0.001 | 100 (0.9) | 1.4 (0.5–3.9) | 0.48534 | 3294 (0.1) | 10.0 (3.7–26.7) | <0.001 |
Alzheimer Disease | 3 (0.9) | 15 (0.3) | 2.8 (0.8–9.6) | 0.09295 | 88 (0.8) | 1.2 (0.4–3.9) | 0.7416 | 6306 (0.2) | 3.9 (1.2–12.1) | 0.01157 |
Asthma | 19 (5.8) | 764 (16.8) | 0.3 (0.2–0.5) | <0.001 | 1138 (9.7) | 0.6 (0.4–0.9) | 0.01651 | 58,241 (2.2) | 2.7(1.7–4.4) | <0.001 |
Atopic Dermatitis | 11 (3.3) | 224 (1.9) | 1.8 (1.0–3.3) | 0.06476 | 4534 (0.2) | 20.3 (11.1–37.1) | <0.001 | |||
Atrial Fibrillation | 18 (5.5) | 187 (4.1) | 1.3 (0.8–2.2) | 0.23646 | 808 (6.9) | 0.8 (0.5–1.3) | 0.31012 | 53,118 (2.0) | 2.9 (1.8–4.6) | <0.001 |
Autistic Disorder | 29 (0.6) | 0 | 0.14617 | 10 (0.1) | 0 | 0.59577 | 1451 (0.1) | 0 | 0.67239 | |
Breast Cancer | 18 (0.4) | 0 | 0.25279 | 62 (0.5) | 0 | 0.18557 | 4966 (0.2) | 0 | 0.43374 | |
Chronic Hepatitis C | 1 (0.3) | 29 (0.6) | 0.5 (0.1–3.5) | 0.45432 | 137 (1.2) | 0.3 (0.0–1.8) | 0.14529 | 6140 (0.2) | 1.3 (0.2–9.4) | 0.7789 |
Chronic Kidney Disease | 20 (6.1) | 187 (4.1) | 1.5 (0.9–2.4) | 0.08793 | 707 (6.0) | 1.0 (0.6–1.6) | 0.97826 | 31,639 (1.2) | 5.4 (3.4–8.5) | <0.001 |
Colon Cancer | 4 (0.1) | 0 | 0.59036 | 23 (0.2) | 0 | 0.42083 | 1842 (0.1) | 0 | 0.63373 | |
Congestive Heart Failure | 18 (5.5) | 132 (2.9) | 1.9 (1.2–3.2) | 0.00924 | 518 (4.4) | 1.2 (0.8–2.0) | 0.3655 | 26,637 (1.0) | 5.7 (3.6–9.2) | <0.001 |
COPD | 21 (6.4) | 209 (4.6) | 1.4 (0.9–2.2) | 0.14046 | 797 (6.8) | 0.9 (0.6–1.5) | 0.7605 | 35,482 (1.3) | 5.1 (3.3–7.9) | <0.001 |
Diabetes Mellitus Type 2 | 24 (7.3) | 346 (7.6) | 1.0 (0.6–1.5) | 0.83347 | 1562 (13.4) | 0.5 (0.3–0.8) | 0.00137 | 70,060 (2.6) | 2.9 (1.9–4.4) | <0.001 |
HIV | 18 (0.4) | 0 | 0.25279 | 63 (0.5) | 0 | 0.18204 | 3463 (0.1) | 0 | 0.51342 | |
Hodgkin’s Disease | 4 (1.2) | 5 (0.1) | 11.2 (3.0–41.8) | <0.001 | 16 (0.1) | 9.0 (3.0–27.0) | <0.001 | 1103 (0.0) | 29.8 (11.1–80.0) | <0.001 |
Hyperlipidemia | 99 (30.1) | 1408 (31.0) | 1.0 (0.8–1.2) | 0.73649 | 4631 (39.6) | 0.7 (0.5–0.8) | <0.001 | 221,792 (8.3) | 4.8 (3.8–6.0) | <0.001 |
Hypertension | 102 (31.0) | 1337 (29.4) | 1.1 (0.8–1.4) | 0.5425 | 4733 (40.5) | 0.7 (0.5–0.8) | <0.001 | 251,808 (9.4) | 4.3 (3.4–5.5) | <0.001 |
IBS | 2 (0.6) | 50 (1.1) | 0.5 (0.1–2.3) | 0.40138 | 198 (1.7) | 0.4 (0.1–1.4) | 0.12925 | 6582 (0.2) | 2.5 (0.6–9.9) | 0.18606 |
Ischemic Heart Disease | 29 (8.8) | 224 (4.9) | 1.9 (1.2–2.8) | 0.00215 | 995 (8.5) | 1.0 (0.7–1.5) | 0.84233 | 50,371 (1.9) | 5.0 (3.4–7.4) | <0.001 |
Ischemic Stroke | - | 14 (0.3) | 0 | 0.31339 | 28 (0.2) | 0 | 0.37435 | 1564 (0.1) | 0 | 0.66064 |
Lung Cancer | 2 (0.6) | 16 (0.4) | 1.7 (0.4–7.6) | 0.46001 | 65 (0.6) | 1.1 (0.3–4.5) | 0.89987 | 5063 (0.2) | 3.2 (0.8–12.9) | 0.08111 |
Lymphomatoid Papulosis | 10 (3.0) | 3 (0.1) | 47.5 (13.0-173.3) | <0.001 | 39 (0.0) | 2147.0 (1062.6–4338.1) | <0.001 | |||
Major Depressive Disorder | 25 (7.6) | 617 (13.6) | 0.5 (0.3–0.8) | 0.00197 | 1720 (14.7) | 0.5 (0.3–0.7) | <0.001 | 80,063 (3.0) | 2.7 (1.8–4.0) | <0.001 |
Malignant Melanoma | 9 (2.7) | 65 (1.4) | 1.9 (1.0–3.9) | 0.0615 | 157 (1.3) | 2.1 (1.0–4.1) | 0.03259 | 7314 (0.3) | 10.2 (3.7–26.7) | <0.001 |
Osteoarthritis | 48 (14.6) | 869 (19.1) | 0.7 (0.5–1.0) | 0.04233 | 3281 (28.0) | 0.4 (0.3–0.6) | <0.001 | 125,515 (4.7) | 3.5 (2.6–4.7) | <0.001 |
Osteoporosis | 10 (3.0) | 261 (5.7) | 0.5 (0.3–1.0) | 0.03882 | 729 (6.2) | 0.5 (0.3–0.9) | 0.01744 | 33,605 (1.3) | 2.5 (1.3–4.6) | 0.00375 |
Psoriasis | 12 (3.6) | 224 (4.9) | 0.7 (0.4–1.3) | 0.29586 | 11,689 (0.4) | 8.6 (4.8–15.3) | <0.001 | |||
Rheumatoid Arthritis | 5 (1.5) | 58 (1.3) | 1.2 (0.5–3.0) | 0.70559 | 390 (3.3) | 0.4 (0.2–1.1) | 0.06869 | 35,498 (1.3) | 1.1 (0.5–2.8) | 0.76249 |
Schizophrenia | 2 (0.6) | 16 (0.4) | 1.7 (0.4–7.6) | 0.46001 | 43 (0.4) | 1.7 (0.4–6.9) | 0.4812 | 2777 (0.1) | 5.9 (1.5–23.6) | 0.00458 |
Venous Thrombosis | 12 (3.6) | 130 (2.9) | 1.3 (0.7–2.3) | 0.41235 | 403 (3.4) | 1.1 (0.6–1.9) | 0.84231 | 22,078 (0.8) | 4.5 (2.6–8.1) | <0.001 |
Vitamin D Deficiency | 29 (8.8) | 838 (18.4) | 0.4 (0.3–0.6) | <0.001 | 2259 (19.3) | 0.4 (0.3–0.6) | <0.001 | 75,560 (2.8) | 3.3 (2.3–4.9) | <0.001 |
References
- Song, S.X.; Willemze, R.; Swerdlow, S.H.; Kinney, M.C.; Said, J.W. Mycosis fungoides: Report of the 2011 Society for Hematopathology/European Association for Haematopathology workshop. Am. J. Clin. Pathol. 2013, 139, 466–490. [Google Scholar] [CrossRef] [PubMed]
- Jawed, S.I.; Myskowski, P.L.; Horwitz, S.; Moskowitz, A.; Querfeld, C. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome): Part I. Diagnosis: Clinical and histopathologic features and new molecular and biologic markers. J. Am. Acad. Dermatol. 2014, 70, e1–e16. [Google Scholar] [CrossRef] [PubMed]
- Criscione, V.D.; Weinstock, M.A. Incidence of cutaneous T-cell lymphoma in the United States, 1973–2002. Arch. Dermatol. 2007, 143, 854–859. [Google Scholar] [CrossRef] [PubMed]
- Korgavkar, K.; Xiong, M.; Weinstock, M. Changing incidence trends of cutaneous T-cell lymphoma. JAMA Dermatol. 2013, 149, 1295–1299. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nikolaou, V.; Marinos, L.; Moustou, E.; Papadavid, E.; Economidi, A.; Christofidou, E.; Gerochristou, M.; Tasidou, A.; Economaki, E.; Stratigos, A.; et al. Psoriasis in patients with mycosis fungoides: A clinicopathological study of 25 patients. J. Eur. Acad. Dermatol. Venereol. 2017, 31, 1848–1852. [Google Scholar] [CrossRef]
- El Tawdy, A.M.; Amin, I.M.; Abdel Hay, R.M.; Hassan, A.S.; Gad, Z.S.; Rashed, L.A. Toll-like receptor (TLR)7 expression in mycosis fungoides and psoriasis: A case-control study. Clin. Exp. Dermatol. 2017, 42, 172–177. [Google Scholar] [CrossRef]
- Cengiz, F.P.; Emiroglu, N. Evaluation of cardiovascular disease risk factors in patients with mycosis fungoides. An. Bras. Dermatol. 2015, 90, 36–40. [Google Scholar] [CrossRef] [Green Version]
- Kim, Y.H.; Liu, H.L.; Mraz-Gernhard, S.; Varghese, A.; Hoppe, R.T. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: Clinical prognostic factors and risk for disease progression. Arch. Dermatol. 2003, 139, 857–866. [Google Scholar] [CrossRef] [Green Version]
- Lindahl, L.M.; Fenger-Gron, M.; Iversen, L. Subsequent cancers, mortality, and causes of death in patients with mycosis fungoides and parapsoriasis: A Danish nationwide, population-based cohort study. J. Am. Acad. Dermatol. 2014, 71, 529–535. [Google Scholar] [CrossRef]
- Boozalis, E.; Tang, O.; Patel, S.; Semenov, Y.R.; Pereira, M.P.; Stander, S.; Kang, S.; Kwatra, S.G. Ethnic differences and comorbidities of 909 prurigo nodularis patients. J. Am. Acad. Dermatol. 2018, 79, 714–719. [Google Scholar] [CrossRef]
- Larson, V.A.; Tang, O.; Stander, S.; Kang, S.; Kwatra, S.G. Association between itch and cancer in 16,925 patients with pruritus: Experience at a tertiary care center. J. Am. Acad. Dermatol. 2019, 80, 931–937. [Google Scholar] [CrossRef] [PubMed]
- Govind, K.; Whang, K.; Khanna, R.; Scott, A.W.; Kwatra, S.G. Atopic dermatitis is associated with increased prevalence of multiple ocular comorbidities. J. Allergy Clin. Immunol. Pract. 2019, 7, 298–299. [Google Scholar] [CrossRef] [PubMed]
- Chronic Conditions. US Centers for Medicare and Medicaid Services. Available online: https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Chronic-Conditions/CC_Main.html (accessed on 27 December 2017).
- Morales Suarez-Varela, M.M.; Llopis Gonzalez, A.; Marquina Vila, A.; Bell, J. Mycosis fungoides: Review of epidemiological observations. Dermatology 2000, 201, 21–28. [Google Scholar] [CrossRef] [PubMed]
- Lim, H.L.J.; Tan, E.S.T.; Tee, S.I.; Ho, Z.Y.; Boey, J.J.J.; Tan, W.P.; Tang, M.B.Y.; Shen, L.; Chan, Y.H.; Tan, S.H. Epidemiology and prognostic factors for mycosis fungoides and Sezary syndrome in a multi-ethnic Asian cohort: A 12-year review. J. Eur. Acad. Dermatol. Venereol. 2019, 33, 1513–1521. [Google Scholar] [CrossRef]
- Amorim, G.M.; Niemeyer-Corbellini, J.P.; Quintella, D.C.; Cuzzi, T.; Ramos-E-Silva, M. Clinical and epidemiological profile of patients with early stage mycosis fungoides. An. Bras. Dermatol. 2018, 93, 546–552. [Google Scholar] [CrossRef]
- Su, C.; Nguyen, K.A.; Bai, H.X.; Cao, Y.; Tao, Y.; Xiao, R.; Karakousis, G.; Zhang, P.J.; Zhang, G. Racial disparity in mycosis fungoides: An analysis of 4495 cases from the US National Cancer Database. J. Am. Acad. Dermatol. 2017, 77, 497–502. [Google Scholar] [CrossRef]
- Larocca, C.; Kupper, T. Mycosis fungoides and Sezary syndrome: An update. Hematol. Oncol. Clin. N. Am. 2019, 33, 103–120. [Google Scholar] [CrossRef]
- Imam, M.H.; Shenoy, P.J.; Flowers, C.R.; Phillips, A.; Lechowicz, M.J. Incidence and survival patterns of cutaneous T-cell lymphomas in the United States. Leuk. Lymphoma 2013, 54, 752–759. [Google Scholar] [CrossRef]
- Huang, A.H.; Kwatra, S.G.; Khanna, R.; Semenov, Y.R.; Okoye, G.A.; Sweren, R.J. Racial disparities in the clinical presentation and prognosis of patients with mycosis fungoides. J. Natl. Med. Assoc. 2019, 111, 633–639. [Google Scholar] [CrossRef]
- Wieser, I.; Oh, C.W.; Talpur, R.; Duvic, M. Lymphomatoid papulosis: Treatment response and associated lymphomas in a study of 180 patients. J. Am. Acad. Dermatol. 2016, 74, 59–67. [Google Scholar] [CrossRef]
- Huang, K.P.; Weinstock, M.A.; Clarke, C.A.; McMillan, A.; Hoppe, R.T.; Kim, Y.H. Second lymphomas and other malignant neoplasms in patients with mycosis fungoides and Sezary syndrome: Evidence from population-based and clinical cohorts. Arch. Dermatol. 2007, 143, 45–50. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hallermann, C.; Kaune, K.M.; Tiemann, M.; Kunze, E.; Griesinger, F.; Mitteldorf, C.; Bertsch, H.P.; Neumann, C. High frequency of primary cutaneous lymphomas associated with lymphoproliferative disorders of different lineage. Ann. Hematol. 2007, 86, 509–515. [Google Scholar] [CrossRef] [PubMed]
- Amber, K.T.; Bloom, R.; Nouri, K. Second primary malignancies in CTCL patients from 1992 to 2011: A SEER-based, population-based study evaluating time from CTCL diagnosis, age, sex, stage, and CD30+ subtype. Am. J. Clin. Dermatol. 2016, 17, 71–77. [Google Scholar] [CrossRef] [PubMed]
- AbuHilal, M.; Walsh, S.; Shear, N. associated hematolymphoid malignancies in patients with lymphomatoid papulosis: A Canadian retrospective study. J. Cutan. Med. Surg. 2017, 21, 507–512. [Google Scholar] [CrossRef]
- Hodak, E.; Lessin, S.; Friedland, R.; Freud, T.; David, M.; Pavlovsky, L.; Shapiro, J.; Cohen, A.D. New insights into associated co-morbidities in patients with cutaneous T-cell lymphoma (mycosis fungoides). Acta Derm. Venereol. 2013, 93, 451–455. [Google Scholar] [CrossRef] [Green Version]
- Smoller, B.R.; Marcus, R. Risk of secondary cutaneous malignancies in patients with long-standing mycosis fungoides. J. Am. Acad. Dermatol. 1994, 30, 201–204. [Google Scholar] [CrossRef]
- Lutsyk, M.; Ben-Yosef, R.; Bergman, R.; Kuten, A.; Bar-Sela, G. Total Skin Electron Irradiation and Sequential Malignancies in Mycosis Fungoides Patients: Longitudinal Study. Clin. Oncol. 2018, 30, 618–624. [Google Scholar] [CrossRef]
- Legendre, L.; Barnetche, T.; Mazereeuw-Hautier, J.; Meyer, N.; Murrell, D.; Paul, C. Risk of lymphoma in patients with atopic dermatitis and the role of topical treatment: A systematic review and meta-analysis. J. Am. Acad. Dermatol. 2015, 72, 992–1002. [Google Scholar] [CrossRef]
- Kechichian, E.; Ezzedine, K. Vitamin D and the Skin: An update for dermatologists. Am. J. Clin. Dermatol. 2018, 19, 223–235. [Google Scholar] [CrossRef]
- Talpur, R.; Cox, K.M.; Hu, M.; Geddes, E.R.; Parker, M.K.; Yang, B.Y.; Armstrong, P.A.; Liu, P.; Duvic, M. Vitamin D deficiency in mycosis fungoides and Sezary syndrome patietns is smiilar to other cancer patients. Clin. Lymphoma Myeloma Leuk. 2014, 14, 518–524. [Google Scholar] [CrossRef]
- Joseph, P.; Leong, D.; McKee, M.; Anand, S.S.; Schwalm, J.D.; Teo, K.; Mente, A.; Yusuf, S. Reducing the global burden of cardiovascular disease, Part 1: The epidemiology AND risk factors. Circ. Res. 2017, 121, 677–694. [Google Scholar] [CrossRef] [PubMed]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Kaul, S.; Belzberg, M.; Hughes, J.-D.M.; Mahadevan, V.; Khanna, R.; Bakhshi, P.R.; Hong, M.S.; Williams, K.A.; Grossberg, A.L.; Kwatra, S.G.; et al. Comorbidities in Mycosis Fungoides and Racial Differences in Co-Existent Lymphomatoid Papulosis: A Cross-Sectional Study of 580 Patients in an Urban Tertiary Care Center. Medicines 2020, 7, 1. https://doi.org/10.3390/medicines7010001
Kaul S, Belzberg M, Hughes J-DM, Mahadevan V, Khanna R, Bakhshi PR, Hong MS, Williams KA, Grossberg AL, Kwatra SG, et al. Comorbidities in Mycosis Fungoides and Racial Differences in Co-Existent Lymphomatoid Papulosis: A Cross-Sectional Study of 580 Patients in an Urban Tertiary Care Center. Medicines. 2020; 7(1):1. https://doi.org/10.3390/medicines7010001
Chicago/Turabian StyleKaul, Subuhi, Micah Belzberg, John-Douglas Matthew Hughes, Varun Mahadevan, Raveena Khanna, Pegah R. Bakhshi, Michael S. Hong, Kyle A. Williams, Annie L. Grossberg, Shawn G. Kwatra, and et al. 2020. "Comorbidities in Mycosis Fungoides and Racial Differences in Co-Existent Lymphomatoid Papulosis: A Cross-Sectional Study of 580 Patients in an Urban Tertiary Care Center" Medicines 7, no. 1: 1. https://doi.org/10.3390/medicines7010001